An observational study in Glioma, sponsored by University of Ulm. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-11.
Sponsored by University of Ulm · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Glioma with a site in Germany — 20 open to participants now, 29 under way, 3 of them phase 3. Glioma · Germany.
Among the 70 studies in Glioma with a site in Germany, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2015, is one of 11 observational ones, reaches primary completion later than 8 of the 28 other live ones, and was the 28th registered.
1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.
Browse Glioma studies →20 of the 70 studies in Glioma with a site in Germany are open now. Recruiting first, the newest first:
iOMEDICO AG · Sites in Germany
Ages 18+
Nationwide Children's Hospital · Sites in Germany, United States, Australia and 3 more countries
Ages 1–21 · Healthy volunteers
LMU Klinikum · Sites in Germany, Austria
Ages 18+
Nationwide Children's Hospital · Sites in Germany, United States, Australia and 2 more countries
Ages 12 mo–39 yrs
Rigel Pharmaceuticals · Sites in Germany, United States, Australia and 4 more countries
Ages 12–39
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 25 · Phase 3 11 · Phase 4 2
First in 1996; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 90 across 274 observational studies indexed under Glioma.
Median enrollment 74 across the 58 interventional studies, 150 across the 11 observational. Of the 33 that completed or were terminated, 10 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 70 have an industry lead sponsor. The 10 most frequent:
University of Ulm is the lead sponsor of 145 studies on the registry; 27 are open to participants now.
University of Ulm has 1 study filed under Glioma — fewer than ten, so there is no comparison to draw.
8 of the studies in Glioma with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04808245German Cancer Research CenterA MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas | 2026-11 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT04655404Nationwide Children's HospitalA Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | 2026-12-01 |
| NCT02686229University of UlmRegistry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 70 studies in Glioma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The LoG-Glio-Registry is based on a network of german hospitals gathering radiological, clinical, epidemiological and molecular data on all patients diagnosed with a low grade glioma.
All adult patients with radiological suspected diagnosis of a low grade glioma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Progression-free survival (PFS)
Time frame: 5yrs
Overall survival (OS)
Time frame: 15yrs
Extent of tumor resection
calculated based on volumetric assessement of tumor in cm³ and residual tumor in pre and postoperative MRI
Time frame: 3yrs
Quality of life (QoL) assessed by the EORTC QLQ C-30/BN-20. (European Organisation for Research and Treatment of Cancer Quality of Life Questionaire C-30
Time frame: 5yrs
Plan to share: No
Started Nov 2015 (actual). Primary completion is estimated for Dec 2026, 133 months after the start.
Of 115 non-industry observational studies under Glioma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 104. This study's planned 133 months is above that.
Counting every sponsor, half of 125 studies reached it within 60 months; a quarter within 29 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.